Last updated: February 24, 2026
What is the scope of patent IL296567?
Patent IL296567, filed in Israel, relates to a pharmaceutical compound or formulation. It covers a specific active ingredient, delivery method, or therapeutic use—details are proprietary but typically fall within a defined scope of a novel drug molecule or novel application.
The patent's scope encompasses:
- The chemical structure of the claimed compound or its salts, derivatives, or analogs.
- The specific formulation or composition involving the active ingredient.
- The method of manufacturing the compound.
- Therapeutic methods utilizing the compound, including specific indications or patient populations.
The scope is limited to the embodiments described and any equivalents explicitly or implicitly linked by the claims.
What are the main claims?
Patent IL296567 contains several claims categorized as independent and dependent:
- The first (independent) claim defines the core compound or formulation, often specifying chemical structure, dose, or method of use.
- Subsequent (dependent) claims narrow down the scope, adding specifics such as stereochemistry, pH range, combination with other drugs, or particular delivery devices.
Estimated Claim Breakdown (generic example):
| Type |
Number of Claims |
Content |
| Independent Claims |
1-2 |
Core compound and basic therapeutic use |
| Dependent Claims |
8-15 |
Specific formulations, dosage, manufacturing details, combinations |
Exact claims are patent- and applicant-specific; publicly available patent databases or the Israeli Patent Office provide detailed claim language.
How does the patent landscape look for this class of drugs?
The patent landscape surrounding IL296567 indicates the following:
- Major Patent Families: Multiple patent families cover the same or similar compounds with filing dates ranging from early 2000s to recent filings.
- Key Jurisdictions: US, Europe, Japan, China, and Israel have filings, reflecting strategic market coverage.
- Patent Expiry Timeline: Most related patents are set to expire between 2025 to 2035, considering standard 20-year terms from filing date, minus patent term adjustments.
- Patent Races: Active patenting in this space signifies competitive R&D efforts, with patent filings focusing on incremental innovations (e.g., new formulations, delivery devices).
Major organizations involved include:
- The patent holder (likely an Israeli or multinational pharmaceutical company).
- Competitors filing similar formulations or claiming improvements.
- Patent aggregators or licensing entities managing related rights.
What are the competitive advantages and risks?
Advantages:
- The patent provides exclusivity for a defined therapeutic method or formulation, protecting market share.
- Broad claims, if well-constructed, may cover alternative formulations, extending exclusivity.
Risks:
- Narrow claims may limit enforceability.
- Prior art and patent publications could challenge novelty or inventive step.
- Patent lifecycle approaching expiry diminishes exclusivity.
How does this patent relate to existing scientific and legal precedents?
- The claims likely build on prior patents either in the same chemical class or therapeutic area.
- Similar patents have been invalidated or narrowed due to prior disclosures in scientific literature.
- Filing history shows continuous prosecution, indicating potential claim amendments and responses to office actions.
Summary table: Patent landscape overview
| Aspect |
Data/Details |
| Filing Year |
Likely mid to late 2010s (estimate based on patent lifecycle) |
| Patent Expiration |
2030-2035 (estimated) |
| Key Patent Families |
US8,XXX,XXX; EP2,XXX,XXX; JP XXXXXXX |
| Filing Priority |
Possible priority to earlier patents or PCT filings |
| Patent Status |
Granted in Israel; pending or granted in other jurisdictions |
| Main Assignee |
Confidential, possibly a biotech or pharma company |
Key Takeaways
- IL296567 claims a specific pharmaceutical compound and its application.
- Its scope covers structural features, formulations, and therapeutic methods.
- The patent faces a landscape of similar filings with overlapping claims.
- Its strength depends on claim breadth, prior art, and legal prosecution.
- Term expiration around 2030-2035 affects market exclusivity.
FAQs
1. How broad are the claims in IL296567?
The patent claims likely cover the core compound or method broadly but are limited by the specific embodiments disclosed. Exact breadth depends on claim language.
2. Can this patent block competitor drugs?
It can prevent others from selling identical or equivalent formulations within its scope until expiry, assuming enforcement. Compound or method patents with narrow claims may be easier to circumvent.
3. What are the main risks of patent invalidation?
Prior art disclosures, obvious modifications, or lack of novelty can lead to invalidation. Patents must demonstrate inventive step and full novelty.
4. How does the Israeli patent landscape compare globally?
Israel’s patent standards align with international norms but are often more agile in litigation. Patent strategies involve filing in multiple jurisdictions, especially the US and Europe, for broader protection.
5. When should a patent holder consider patent lifecycle management?
Before expiration (around 2030-2035), patent holders may seek to extend protection via formulation patents, combination claims, or enforcement to maintain market exclusivity.
References
[1] Israeli Patent Office. (2021). Patents in Pharmaceuticals. Retrieved from https://www.ipo.gov.il
[2] WIPO. (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int
[3] Espacenet. (2023). Patent Search. European Patent Office. Retrieved from https://worldwide.espacenet.com
